AR015241A1 - Antagonistas del receptor de vitronectina composicion farmaceutica que los contiene, procedimiento para su preparacion y su empleo para la fabricacion deun medicamento. - Google Patents
Antagonistas del receptor de vitronectina composicion farmaceutica que los contiene, procedimiento para su preparacion y su empleo para la fabricacion deun medicamento.Info
- Publication number
- AR015241A1 AR015241A1 ARP990101019A ARP990101019A AR015241A1 AR 015241 A1 AR015241 A1 AR 015241A1 AR P990101019 A ARP990101019 A AR P990101019A AR P990101019 A ARP990101019 A AR P990101019A AR 015241 A1 AR015241 A1 AR 015241A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- het
- cycloalkyl
- co2rg
- crg2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Abstract
Antagonistas del receptor de vitronectina de formula (I) que son utiles en el tratamiento de osteosporosis: (I) en la que R* es II, X es CRR, NR o S;Y es CRR, NR o S; A es H, halo, ORg, -SRg, -CN, -NRgRk, -NO2, -CF3, -S(O)rCF3, -CO2Rg, -CORg, -CONRg2, -alquilo C1-6, -alquil C0-6-Ar, -alquil C0-6-Het,-alquil C0-6-cicloalquilo C3-6, -S(O)kRg,o CH2N(Rf)2;R1 es-alquil C0-6-Het,-alquil C0-6-Ar, -alquilo C1-6, -H, -CN, -CH=CH2, -C=CH o -S(0)kRg; R2 es III, W es-(CHRg)a-U-(CHRg)b-; U está ausente o esCO, CRg2, C(=CRg2), S(O)k, O, NRg, CRgORg, CR9(ORk)CRg2, CRgCRg(ORk), C(O)CRg2, CRg2C(O), CONRi, NRiCO, OC(O), C(O)O,C(S)O, OC(S), C(S)NRg, NRgC(S), S(O)2NRg, NRgS(O)2, N=N, NRgNRg, NRgNRg2, CRg2CRg, CRg2O, OCRg2, C=C, CRg=CRg, Ar o Het; G es NRe, su o; Rg es H, alquiloC1-6, cilcoalquil C3-7-alquilo C0-6 o Ar-alquilo C0-6; Rk es Rg, -C(O)Rg, o -C(O)ORf; Ri es H, alquilo C1-6, Het-alquilo C0-6, cicloalquil C3-7-alquilo C0-6,Ar-alquil C0-6 o alquilo C1-6 sustituido con uno a tres grupos seleccionados entre halogeno, CN, NRg2, ORg, SRg, CO2Rg y CON(Rg)2; Rf es H, alquilo C1-6 oAr-alquilo C0-6; Re es H, alquilo C1-6, Ar-alquilo C0-6, Het-alquilo C0-6, cicloalquilo C3-7-alquilo C0-6 o (CH2)kCO2Rg; Rb y Rc se seleccionanindependientemente entreH, alquilo C1-6, Ar-alquil C0-6, Het-alquilo C0-6, cicloalquil C3-6-alquilo C0-6, halogeno, CF3, ORf, S(O)kRf, CORf, NO2, N(Rf)2,CO(NRf)2,CH2N(Rf)2,o Rb y Rc están unidos entre sí para formar un anillo carbocíclico o heterocíclico,aromático o no aromático,de 5 o 6 miembros,opcionalmentesustituido hasta con 3 sustituyentes elegidos entre halogeno, CF3, alquilo C1-4, ORf, S(O)kRf, CORf, OH, NO2, N/Rf)2, CON(Rf)2 y CH2N(Rf); o metilendioxi; Q1,Q2, Q3 y Q4 son independientemente N o C-Ry, siempre que no más de uno de Q1,Q2,Q3 y Q4 sea N; R es H, alquilo C1-6, Ar-alquilo C0-6 o cicloalquil C3-6-alquilo C0-6; R es R, -C(O)R o -C(O)OR; Ry es H, halo, -ORg, -SRg, -CN, -NRgRk, -NO2, -CF3,-CF3S(O)r-, -CO2Rg o -CONRg2, o alquilo C1-6 opcionalmentesustituido con halo ORg, SRg,-CN,-NRgR, -NO2,-CF3,RS(O)r-, -CO2Rg, -CORg, o -CONRg2; a es 0, 1 o 2; b es 0, 1 o 2; k es 0, 1 o 2; r es 0, 1 o 2; s es 0, 1 o
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7761098P | 1998-03-10 | 1998-03-10 | |
| US9606398P | 1998-08-11 | 1998-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR015241A1 true AR015241A1 (es) | 2001-04-18 |
Family
ID=26759473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101019A AR015241A1 (es) | 1998-03-10 | 1999-03-10 | Antagonistas del receptor de vitronectina composicion farmaceutica que los contiene, procedimiento para su preparacion y su empleo para la fabricacion deun medicamento. |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1061921A4 (es) |
| JP (1) | JP2002506033A (es) |
| KR (1) | KR20010041812A (es) |
| CN (1) | CN1299282A (es) |
| AP (1) | AP2000001898A0 (es) |
| AR (1) | AR015241A1 (es) |
| AU (1) | AU758498B2 (es) |
| BG (1) | BG104824A (es) |
| BR (1) | BR9908636A (es) |
| CA (1) | CA2323208A1 (es) |
| CO (1) | CO5080762A1 (es) |
| DZ (1) | DZ2741A1 (es) |
| EA (1) | EA200000921A1 (es) |
| HU (1) | HUP0101143A3 (es) |
| ID (1) | ID26223A (es) |
| IL (1) | IL138245A0 (es) |
| NO (1) | NO20004503L (es) |
| OA (1) | OA12189A (es) |
| PE (1) | PE20000323A1 (es) |
| PL (1) | PL342881A1 (es) |
| SK (1) | SK13292000A3 (es) |
| TR (1) | TR200002625T2 (es) |
| UY (2) | UY25421A1 (es) |
| WO (1) | WO1999045927A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19939980A1 (de) | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Inhibitoren des Integrins alphavbeta¶3¶ |
| DE19939981A1 (de) * | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Neue Inhibitoren des Integrins alphavß3 |
| EG24179A (en) * | 1999-09-07 | 2008-09-28 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
| US6881736B1 (en) | 1999-09-07 | 2005-04-19 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| GB9930570D0 (en) * | 1999-12-23 | 2000-02-16 | Pfizer Ltd | Therapy |
| US6448278B2 (en) | 1999-12-23 | 2002-09-10 | Pfizer Inc. | Procollagen C-proteinase inhibitors |
| FR2808798A1 (fr) * | 2000-05-09 | 2001-11-16 | Hoechst Marion Roussel Inc | Nouveaux derives antagonistes du recepteur de la vitronectine |
| US6900232B2 (en) | 2000-06-15 | 2005-05-31 | Pharmacia Corporation | Cycloalkyl alkanoic acids as integrin receptor antagonists |
| US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
| US6645993B2 (en) | 2001-03-30 | 2003-11-11 | Warner-Lambert Company | 3-heterocyclylpropanohydroxamic acid PCP inhibitors |
| US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
| US20070275956A1 (en) * | 2003-10-14 | 2007-11-29 | Lohray Braj B | Novel Heterocyclic Compounds |
| JP4853284B2 (ja) * | 2004-03-05 | 2012-01-11 | 大正製薬株式会社 | チアゾール誘導体 |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| KR20080004554A (ko) | 2005-04-20 | 2008-01-09 | 얀센 파마슈티카 엔.브이. | 불소화 피리딘 ｎ―옥사이드 트롬빈 모듈레이터 및 질소를함유하는 헤테로아릴의 ｎ―산화 방법 |
| EP3040329B1 (en) * | 2013-08-29 | 2018-10-10 | Kyoto Pharmaceutical Industries, Ltd. | Aromatic compound and use thereof in the treatment of disorders associated with bone metabolism |
| PT3929196T (pt) | 2013-09-24 | 2023-09-11 | Fujifilm Corp | Composição farmacêutica de um novo composto contendo azoto ou seu sal, ou seu complexo de metal |
| KR20160147007A (ko) | 2014-05-30 | 2016-12-21 | 화이자 인코포레이티드 | 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체 |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1209063A (zh) * | 1995-12-29 | 1999-02-24 | 史密丝克莱恩比彻姆公司 | 玻连蛋白受体拮抗剂 |
| KR19990076876A (ko) * | 1995-12-29 | 1999-10-25 | 스티븐 베네티아너 | 비트로넥틴 수용체 길항제 |
-
1999
- 1999-03-10 EA EA200000921A patent/EA200000921A1/ru unknown
- 1999-03-10 PL PL99342881A patent/PL342881A1/xx unknown
- 1999-03-10 BR BR9908636-0A patent/BR9908636A/pt not_active Application Discontinuation
- 1999-03-10 AR ARP990101019A patent/AR015241A1/es not_active Application Discontinuation
- 1999-03-10 JP JP2000535342A patent/JP2002506033A/ja not_active Withdrawn
- 1999-03-10 CA CA002323208A patent/CA2323208A1/en not_active Abandoned
- 1999-03-10 AU AU29033/99A patent/AU758498B2/en not_active Ceased
- 1999-03-10 ID IDW20001737A patent/ID26223A/id unknown
- 1999-03-10 WO PCT/US1999/005232 patent/WO1999045927A1/en not_active Application Discontinuation
- 1999-03-10 IL IL13824599A patent/IL138245A0/xx unknown
- 1999-03-10 HU HU0101143A patent/HUP0101143A3/hu unknown
- 1999-03-10 SK SK1329-2000A patent/SK13292000A3/sk unknown
- 1999-03-10 PE PE1999000188A patent/PE20000323A1/es not_active Application Discontinuation
- 1999-03-10 CN CN99805833A patent/CN1299282A/zh active Pending
- 1999-03-10 AP APAP/P/2000/001898A patent/AP2000001898A0/en unknown
- 1999-03-10 UY UY25421A patent/UY25421A1/es unknown
- 1999-03-10 KR KR1020007010091A patent/KR20010041812A/ko not_active Application Discontinuation
- 1999-03-10 OA OA00000248A patent/OA12189A/en unknown
- 1999-03-10 DZ DZ990042A patent/DZ2741A1/xx active
- 1999-03-10 EP EP99909952A patent/EP1061921A4/en not_active Withdrawn
- 1999-03-10 CO CO99014712A patent/CO5080762A1/es unknown
- 1999-03-10 TR TR2000/02625T patent/TR200002625T2/xx unknown
- 1999-05-19 UY UY25519A patent/UY25519A1/es unknown
-
2000
- 2000-09-08 NO NO20004503A patent/NO20004503L/no unknown
- 2000-10-03 BG BG104824A patent/BG104824A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010041812A (ko) | 2001-05-25 |
| AU758498B2 (en) | 2003-03-20 |
| CN1299282A (zh) | 2001-06-13 |
| UY25519A1 (es) | 1999-12-13 |
| CO5080762A1 (es) | 2001-09-25 |
| DZ2741A1 (fr) | 2003-09-08 |
| JP2002506033A (ja) | 2002-02-26 |
| EP1061921A4 (en) | 2005-03-30 |
| BR9908636A (pt) | 2002-01-08 |
| WO1999045927A1 (en) | 1999-09-16 |
| NO20004503D0 (no) | 2000-09-08 |
| AP2000001898A0 (en) | 2000-09-30 |
| PE20000323A1 (es) | 2000-05-24 |
| OA12189A (en) | 2006-05-09 |
| HUP0101143A3 (en) | 2002-12-28 |
| IL138245A0 (en) | 2001-10-31 |
| SK13292000A3 (sk) | 2001-06-11 |
| EP1061921A1 (en) | 2000-12-27 |
| UY25421A1 (es) | 2001-07-31 |
| EA200000921A1 (ru) | 2001-04-23 |
| ID26223A (id) | 2000-12-07 |
| TR200002625T2 (tr) | 2000-12-21 |
| AU2903399A (en) | 1999-09-27 |
| NO20004503L (no) | 2000-10-10 |
| BG104824A (en) | 2001-05-31 |
| CA2323208A1 (en) | 1999-09-16 |
| PL342881A1 (en) | 2001-07-16 |
| HUP0101143A2 (hu) | 2001-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR015241A1 (es) | Antagonistas del receptor de vitronectina composicion farmaceutica que los contiene, procedimiento para su preparacion y su empleo para la fabricacion deun medicamento. | |
| PA8546601A1 (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
| PA8586401A1 (es) | 4-piperazinilbencenosulfonilindoles y uso de los mismos | |
| PA8547901A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
| ATE380818T1 (de) | Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose | |
| PE20040832A1 (es) | Derivados de indolil pirazinona | |
| AR038341A1 (es) | Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l | |
| PE10499A1 (es) | Antagonistas del receptor de vitronectina | |
| PE20061298A1 (es) | Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c | |
| AR050913A1 (es) | Compuestos derivados de tiazolpiridina como activadores de glucoquinasa; composiciones farmaceuticas que los contienen y su uso en medicamentos para el tratamiento de la diabetes tipo ii | |
| AR059178A1 (es) | Benzotiazoles heteroaril sustituidos, composiciones farmaceuticas que los contienen,y usos terapeuticos, entre ellos, en el tratamiento y/o prevencion de la enfermedad de alzheimer. | |
| RS50290B (sr) | Novi derivati 1,3-dihidro-2h-indol-2-ona i njihova upotreba kao liganada za v1b i v1a receptore arginin-vazopresina | |
| RU2007138937A (ru) | Производные 1-бензилиндол-2-карбоксамида | |
| HRP20000896B1 (en) | Adenosine derivatives | |
| DK1404317T3 (da) | 5-Halogentryptaminderivater til anvendelse som ligander af 5-HT6- og/eller 5-HT7-serotoninreceptorer | |
| AR033791A1 (es) | Compuestos de acidos oxamicos y derivados como ligandos de receptores tiroideos,su uso. composicion y estuche que lo contiene | |
| CR8505A (es) | Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
| AR004735A1 (es) | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. | |
| AR065948A1 (es) | Antagonistas del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos | |
| PE20030610A1 (es) | Derivados de 3-azabiciclo[3.1.0]hexano con afinidad a los receptores opioides | |
| AR016433A1 (es) | Procedimiento para el tratamiento de la impotencia y composiciones. | |
| AR056103A1 (es) | Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1 | |
| PE20060632A1 (es) | Derivados de arilsulfonilestilbeno como antagonistas de los receptores 5-ht2a | |
| AR048232A1 (es) | Piperidinilcarbonil- pirrolidinas y su uso como agonistas de melanocortina cr4 | |
| PA8463001A1 (es) | Compuestos de eteres ciclicos de piperidinilaminometil trifluorometilo como antagonistas de la sustancia p |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |